Glycine transporter inhibition reverses ketamine-induced working memory deficits

NeuroReport

Volumn 21, Issue 5, 2010, Pages 390-394

  Roberts, Brooke M ^a,b   Shaffer, Christopher L ^c   Seymour, Patricia A ^c   Schmidt, Christopher J ^c   Williams, Graham V ^a,b   Castner, Stacy A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c PFIZER INC   (United States)

Author keywords

Cognition; GlyT1; NMDA; Nonhuman primate; Prefrontal cortex; Schizophrenia

Indexed keywords

GLYCINE TRANSPORTER; KETAMINE; PF 3463275; PLACEBO;

AMNESIA; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; HALLUCINATION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SCHIZOPHRENIA; SPATIAL MEMORY; WORKING MEMORY;

ANALYSIS OF VARIANCE; ANIMALS; AZABICYCLO COMPOUNDS; DISEASE MODELS, ANIMAL; FEMALE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HALLUCINATIONS; IMIDAZOLES; MACACA MULATTA; MEMORY DISORDERS; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; OXIDES; POTASSIUM; SCHIZOPHRENIA; TANTALUM; TREATMENT OUTCOME;

EID: 77949431787     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e3283381a4e     Document Type: Article

References (25)

1. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199-214.
2. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005a; 179:303-309.
3. Taffe MA, Davis SA, Gutierrez T, Gold LH. Ketamine impairs multiple cognitive domains in rhesus monkeys. Drug Alcohol Depend 2002; 68:175-187.
4. Buccafusco JJ, Terry AV Jr. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem Pharmacol 2009; 78:852-862.
5. Chen L, Muhlhauser M, Yang CR. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 2003; 89:691-703.
6. Kinney GG, Sur C, Burno M, Mallorga PJ,Williams JB, Figueroa DJ, et al. The glycine transporter type 1 inhibitor N-[3-(40-fluorophenyl)-3-(40- phenylphenoxy) propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 2003; 23:7586-7591.
7. Wang XJ. Synaptic basis of cortical persistent activity: the importance of NMDA receptors to working memory. J Neurosci 1999; 19:9587-9603.
8. Tseng KY, O'Donnell P. Post-pubertal emergence of prefrontal cortical up states induced by D1-NMDA co-activation. Cereb Cortex 2005; 15:49-57.
9. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44:1081-1089.
10. Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006; 59:230-234.
11. Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol 2008; 18:414-421.
12. Konradsson A, Marcus MM, Hertel P, Svensson TH, Jardemark KE. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 2006; 60:102-108.
13. Tsai GE, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55:452-456.
14. Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60:645-649.
15. Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, Tsai GE. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 2008; 63:9-12.
16. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2009; 4:1-10. [Epub ahead of print].
17. Manahan-Vaughan D, Wildförster V, Thomsen C. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). Eur J Neurosci 2008; 28:1342-1350.
18. Karasawa J, Hashimoto K, Chaki S. D-serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 2008; 186:78-83.
19. Singer P, Feldon J, Yee BK. The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice. Psychopharmacology (Berl) 2009; 202:371-384.
20. Gozzi A, Herdon H, Schwarz A, Bertani S, Crestan V, Turrini G, Bifone A. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology (Berl) 2008; 201:273-284.
21. Lowe JA III, Hou X, Schmidt C, Tingley FD, McHardy S, Kalman M, et al. The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett 2009; 19:2974-2976.
22. Castner SA, Goldman-Rakic PS. Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacol 1999; 20:10-28.
23. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr Bull 2000; 26:119-136.
24. Wylie GR, Clark EA, Butler PD, Javitt DC. Schizophrenia patients show task switching deficits consistent with N-methyl-D-aspartate system dysfunction but not global executive deficits: implications for pathophysiology of executive dysfunction in schizophrenia. Schizophr Bull 2008. [Epub ahead of print].
25. Barch DM, Carter CS, Arnsten A, Buchanan RW, Cohen JD, Geyer M, et al. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull 2009; 35:109-114.